Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 13;9:1059028. doi: 10.3389/fmed.2022.1059028

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 de Oliveira, vom Stein, Rebollido-Rios, Lobastova, Lettau, Janssen, Wagle, Nguyen, Hallek and Hansen.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Lyn contributes to generate chronic lymphocytic leukemia (CLL)-supportive extracellular vesicles (EVs). (A) Primary CLL cells (0.3 × 10^6/well in a 96-well plate) of 11 different donors were cultivated in RPMI-1640 medium with 10% FBS and a dilution series of purified EVs from HS-5 cells as indicated. After 24 h the cell viability was determined with CellTiter-Glo 2.0. Statistics: Brown–Forsythe ANOVA test. (B) The differential effect of EVs (4 μg/ml) from Lyn-proficient and -deficient HS-5 cells on the viability of primary CLL cells was compared with untreated CLL cells in a kinetic study (0–96 h). At the end of the indicated incubation period, the cell viability was determined with CellTiter-Glo 2.0. Statistics: two-tailed, unpaired t-test with Welch’s correction at indicated time points (^***P < 0.001, ^****P < 0.0001).